Screener / SEC EDGAR /CIK 0001588978 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

PROCEPT BioRobotics Corp PRCT

Compare with peers Embed
What it said it expected, against what it reported

4 targets with a reported result

Releases of the last 3 years
Above the range 3 above the last range given
Within the range 0 of 4 range targets
Below the range 1 below the last range given

The numbers PRCT said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
Given $410.00M to $430.00M release Nov 4, 2025
Lowered $390.00M to $410.00M release Feb 25, 2026
Kept $390.00M to $410.00M release Apr 29, 2026
Kept $390.00M to $410.00M release Aug 4, 2026
Kept $390.00M to $410.00M release Nov 4, 2026
– Not reported yet
The company's words
Issued fiscal year 2026 total revenue guidance in the range of $410 to $430 million, representing growth of 26% to 32% compared to fiscal 2025 revenue guidance of $325.5 million. release Nov 4, 2025
Considering these factors, together with the short-term disruption associated with the sales force realignment, we are resetting our 2026 guidance to $390 to $410 million, representing annual growth of 27% to 33%. release Feb 25, 2026
The Company continues to expect revenue for the full year 2026 to be in the range of $390 million to $410 million, which represents growth of 27% to 33% compared to the prior year period release Apr 29, 2026
The Company reiterates revenue for the full year 2026 to be in the range of $390 million to $410 million, which represents growth of 27% to 33% compared to the prior year period release Aug 4, 2026
The Company reiterates revenue for the full year 2026 to be in the range of $390 million to $410 million, which represents growth of 27% to 33% compared to the prior year period release Nov 4, 2026
Revenue
Q1 of fiscal 2026
Given $79.00M to $82.00M release Feb 25, 2026
$83.13M
10-Q filed 2026-04-30
Above the range
The company's words
Total revenue for the first quarter of 2026 is expected to be in the range of $79 million to $82 million dollars, which represents growth of 14% to 19% to the prior year period. release Feb 25, 2026
EBITDA (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $35.00M release Feb 25, 2025
– No standard number
The company's words
2025 Financial Guidance … The Company projects full year 2025 Adjusted EBITDA loss to be approximately $ 35 million release Feb 25, 2025
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $320.00M release Feb 25, 2025
Raised $323.00M release Apr 24, 2025
Raised $325.50M release Aug 6, 2025
$308.05M
10-K filed 2026-02-26
Below the range
The company's words
2025 Financial Guidance … The Company projects revenue for the full year 2025 to be approximately $320 million, which would represent 42% growth over the Company’s prior year revenue release Feb 25, 2025
Full Year 2025 Financial Guidance … The Company projects revenue for the full year 2025 to be $323.0 million, which represents 44% growth over the Company’s prior year revenue. release Apr 24, 2025
Full Year 2025 Financial Guidance … The Company projects revenue for the full year 2025 revenue to be approximately $325.5 million, which represents 45% growth over the Company’s prior year revenue. release Aug 6, 2025
Revenue
Q1 of fiscal 2025
Given $65.50M release Feb 25, 2025
$69.16M
10-Q filed 2025-05-02
Above the range
The company's words
First Quarter of 2025 Financial Guidance … The Company projects revenue for the first quarter of 2025 to be approximately $65.5 million release Feb 25, 2025
EBITDA (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $60.00M release Oct 28, 2024
– No standard number
The company's words
Increased fiscal year 2024 Adjusted EBITDA guidance to a loss of $60.0 million release Oct 28, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $217.00M release Aug 1, 2024
Raised $222.50M to $223.00M release Oct 28, 2024
$224.50M
10-K filed 2025-02-27
Above the range
The company's words
Increased fiscal year 2024 total revenue guidance to approximately $217 million and improved EBITDA guidance to a loss of $67.5 million release Aug 1, 2024
Increased fiscal year 2024 total revenue guidance range to $222.5 million to $223.0 million release Oct 28, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (11 releases since 2024-08-01), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRCT/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.